Neuroimaging studies of acute effects of THC and CBD in humans and animals: A systematic review

Current Pharmaceutical Design

Volumn 20, Issue 13, 2014, Pages 2168-2185

  Batalla, A ^a,b   Crippa, J A ^c,d   Busatto, G F ^c   Guimaraes F S ^c,d   Zuardi, A W ^c,d   Valverde, O ^e,f   Atakan, Z ^g   Mcguire, P K ^g   Bhattacharyya, S ^g   Martin Santos R ^a,d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d National Institute for Translational Medicine (INCT TM CNPq)   (Brazil)

^e UNIVERSITAT POMPEU FABRA   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Animals; Brain function; Cannabis; Cannabis users; CBD; Neuroimaging; Systematic review; THC

Indexed keywords

CANNABIDIOL; DOPAMINE; TETRAHYDROCANNABINOL; CANNABINOID; CANNABIS; DRONABINOL;

ARTICLE; BRAIN BLOOD FLOW; BRAIN FUNCTION; CANNABIS USE; COGNITION; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GLUCOSE METABOLISM; HUMAN; MOTOR PERFORMANCE; NEUROCHEMISTRY; NEUROMODULATION; NEUROPHYSIOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; SYSTEMATIC REVIEW; TASK PERFORMANCE; ANIMAL; BRAIN; BRAIN CIRCULATION; DRUG EFFECTS; NEUROIMAGING; PHYSIOLOGY; PROCEDURES; SECRETION (PROCESS); TOXICITY;

ANIMALS; BRAIN; CANNABINOIDS; CANNABIS; CEREBROVASCULAR CIRCULATION; COGNITION; DOPAMINE; DRONABINOL; HUMANS; NEUROIMAGING;

EID: 84903750539     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990432     Document Type: Article

References (268)

1. United Nations Office on Drugs and Crime. World drug report 2012. UNODC, Vienna 2012. Access date: 20 January 2013. Available from: http://www.unodc.org/unodc/en/data-andanalysis/WDR-2012.html.
2. European Monitoring Centre for Drugs and Drug Addiction. The state of the drugs problem in Europe. EMCDDA, Lisbon 2012. Access date: 29 January 2013. Available from: http://www.emcdda.europa.eu/publications/annual-report/2012.
3. Mechoulam R, Gaoni Y. Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 1967; 25: 175-213.
4. Mechoulam R, Parker LA. The Endocannabinoid System and the Brain. Annu Rev Psychol 2012; Jul 12. [Epub ahead of print].
5. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971; 93(1): 217-24.
6. Martin-Santos R, Crippa JA, Batalla A, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 2012; 18(32): 4966-79.
7. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 2006; 188(4): 425-44.
8. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 2009; 23(3): 266-77.
9. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352(9140): 1611-6.
10. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011; 25(1): 121-30.
11. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006; 39(4): 421-9.
12. Zuardi AW, Crippa JA, Hallak JE, et al. A critical review of the antipsychotic effects of Cannabidiol: 30 years of a translational investigation. Curr Pharm Des 2012; 18(32): 5131-40.
13. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35(3): 764-74.
14. Ilan AB, Gevins A, Coleman M, ElSohly MA, de WH. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 2005; 16(5-6): 487-96.
15. Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008; 53(1): 90-4.
16. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009; 195(6): 488-91.
17. Batalla A, Garcia-Rizo C, Castellvi P, et al. Screening for substance use disorders in first-episode psychosis: Implications for readmission. Schizophr Res 2013; 146(1-3): 125-31.
18. Burns HD, Van LK, Sanabria-Bohorquez S, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 2007; 104(23): 9800-5.
19. El Khoury MA, Gorgievski V, Moutsimilli L, Giros B, Tzavara ET. Interactions between the cannabinoid and dopaminergic systems: Evidence from animal studies. Prog Neuropsychopharmacol Biol Psychiatry 2012; 38(1): 36-50.
20. Reguero L, Puente N, Elezgarai I, et al. GABAergic and cortical and subcortical glutamatergic axon terminals contain CB1 cannabinoid receptors in the ventromedial nucleus of the hypothalamus. PLoS One 2011; 6(10): e26167.
21. Fadda P, Scherma M, Spano MS, et al. Cannabinoid selfadministration increases dopamine release in the nucleus accumbens. Neuroreport 2006; 17(15): 1629-32.
22. Morrison PD, Murray RM. From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophr Bull 2009; 35(4): 668-74.
23. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310(5746): 329-32.
24. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153(2): 199-215.
25. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998; 285(1): 285-92.
26. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol--recent advances. Chem Biodivers 2007; 4(8): 1678-92.
27. van OJ, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468(7321): 203-12.
28. Bhattacharyya S, Atakan Z, Martin-Santos R, et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 2012; 17(12): 1152-5.
29. Batalla A, Soriano-Mas C, Lopez-Sola M, et al. Modulation of brain structure by catechol-O-methyltransferase Val(158) Met polymorphism in chronic cannabis users. Addict Biol 2013; Jan 14. [Epub ahead of print].
30. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, McGuire PK. Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man: a Critical Review of Neuroimaging Studies. Curr Pharm Des 2012; 18(32): 5045-54.
31. Chang L, Chronicle EP. Functional imaging studies in cannabis users. Neuroscientist 2007; 13(5): 422-32.
32. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev 2007; 17(3): 347-61.
33. Jager G, Ramsey NF. Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Curr Drug Abuse Rev 2008; 1(2): 114-23.
34. Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yucel M. Structural MRI findings in long-term cannabis users: what do we know? Subst Use Misuse 2010; 45(11): 1787-808.
35. Martin-Santos R, Fagundo AB, Crippa JA, et al. Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 2010; 40(3): 383-98.
36. Quickfall J, Crockford D. Brain neuroimaging in cannabis use: a review. J Neuropsychiatry Clin Neurosci 2006; 18(3): 318-32.
37. Bhattacharyya S, Crippa JA, Martin-Santos R, Winton-Brown T, Fusar-Poli P. Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des 2009; 15(22): 2603-14.
38. Batalla A, Bhattacharyya S, Yucel M, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One 2013; 8(2): e55821.
39. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
40. Acquas E, Pisanu A, Marrocu P, Di CG. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur J Pharmacol 2000; 401(2): 179-85.
41. Acquas E, Pisanu A, Marrocu P, Goldberg SR, Di CG. Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. Eur J Pharmacol 2001; 419(2-3): 155-61.
42. Carta G, Nava F, Gessa GL. Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats. Brain Res 1998; 809(1): 1-4.
43. Cenni G, Blandina P, Mackie K, et al. Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain. Eur J Neurosci 2006; 24(6): 1633-44.
44. Chikai T, Oishi R, Saeki K. Microdialysis study of the effects of sedative drugs on extracellular histamine in the striatum of freely moving rats. J Pharmacol Exp Ther 1993; 266(3): 1277-81.
45. Degroot A, Kofalvi A, Wade MR, et al. CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol Pharmacol 2006; 70(4): 1236-45.
46. Egashira N, Mishima K, Katsurabayashi S, et al. Involvement of 5-hydroxytryptamine neuronal system in Delta(9)-tetrahydrocannabinol-induced impairment of spatial memory. Eur J Pharmacol 2002; 445(3): 221-9.
47. Ferraro L, Tomasini MC, Cassano T, et al. Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gammaaminobutyric acid levels. J Neurosci Res 2001; 66(2): 298-302.
48. Gessa GL, Casu MA, Carta G, Mascia MS. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur J Pharmacol 1998; 355(2-3): 119-24.
49. Inui K, Egashira N, Mishima K, et al. The serotonin1A receptor agonist 8-OHDPAT reverses delta 9-tetrahydrocannabinol-induced impairment of spatial memory and reduction of acetylcholine release in the dorsal hippocampus in rats. Neurotox Res 2004; 6(2): 153-8.
50. Merroun I, Errami M, Hoddah H, et al. Influence of intracerebroventricular or intraperitoneal administration of cannabinoid receptor agonist (WIN 55,212-2) and inverse agonist (AM 251) on the regulation of food intake and hypothalamic serotonin levels. Br J Nutr 2009; 101(10): 1569-78.
51. Mishima K, Egashira N, Matsumoto Y, Iwasaki K, Fujiwara M. Involvement of reduced acetylcholine release in Delta9-tetrahydrocannabinol-induced impairment of spatial memory in the 8-arm radial maze. Life Sci 2002; 72(4-5): 397-407.
52. Murillo-Rodriguez E, Blanco-Centurion C, Sanchez C, Piomelli D, Shiromani PJ. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep 2003; 26(8): 943-7.
53. Oropeza VC, Page ME, Van Bockstaele EJ. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res 2005; 1046(1-2): 45-54.
54. Page ME, Oropeza VC, Sparks SE, et al. Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav 2007; 86(1): 162-8.
55. Page ME, Oropeza VC, Van Bockstaele EJ. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett 2008; 431(1): 1-5.
56. Pisanu A, Acquas E, Fenu S, Di CG. Modulation of Delta(9)-THCinduced increase of cortical and hippocampal acetylcholine release by micro opioid and D(1) dopamine receptors. Neuropharmacology 2006; 50(6): 661-70.
57. Sano K, Mishima K, Koushi E, et al. Delta 9-tetrahydrocannabinolinduced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Neuroscience 2008; 151(2): 320-8.
58. Solinas M, Zangen A, Thiriet N, Goldberg SR. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol. Eur J Neurosci 2004; 19(12): 3183-92.
59. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG. The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 2001; 426(3): R3-R4.
60. Tzavara ET, Davis RJ, Perry KW, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003; 138(4): 544-53.
61. Valverde O, Noble F, Beslot F, et al. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 2001; 13(9): 1816-24.
62. Verrico CD, Jentsch JD, Dazzi L, Roth RH. Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat. Synapse 2003; 48(4): 178-83.
63. Wade MR, Tzavara ET, Nomikos GG. Cannabinoids reduce cAMP levels in the striatum of freely moving rats: an in vivo microdialysis study. Brain Res 2004; 1005(1-2): 117-23.
64. Aasly J, Storsaeter O, Nilsen G, Smevik O, Rinck P. Minor structural brain changes in young drug abusers. A magnetic resonance study. Acta Neurol Scand 1993; 87(3): 210-4.
65. Amen DG, Waugh M. High resolution brain SPECT imaging of marijuana smokers with AD/HD. J Psychoactive Drugs 1998; 30(2): 209-14.
66. Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J. The impact of early-onset cannabis use on functional brain correlates of working memory. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(6): 837-45.
67. Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J. Altered parahippocampal functioning in cannabis users is related to the frequency of use. Psychopharmacology (Berl) 2010; 209(4): 361-74.
68. Campbell AM, Evans M, Thomson JL, Williams MJ. Cerebral atrophy in young cannabis smokers. Lancet 1971; 2(7736): 1219-24.
69. Cheetham A, Allen NB, Whittle S, et al. Orbitofrontal Volumes in Early Adolescence Predict Initiation of Cannabis Use: A 4-Year Longitudinal and Prospective Study. Biol Psychiatry 2011.
70. Chung T, Geier C, Luna B, et al. Enhancing response inhibition by incentive: comparison of adolescents with and without substance use disorder. Drug Alcohol Depend 2011; 115(1-2): 43-50.
71. Churchwell JC, Lopez-Larson M, Yurgelun-Todd DA. Altered frontal cortical volume and decision making in adolescent cannabis users. Front Psychol 2010; 1: 225.
72. Cousijn J, Goudriaan AE, Ridderinkhof KR, et al. Neural responses associated with cue-reactivity in frequent cannabis users. Addict Biol 2012; Jan 20. [Epub ahead of print].
73. Demirakca T, Sartorius A, Ende G, et al. Diminished gray matter in the hippocampus of cannabis users: Possible protective effects of cannabidiol. Drug Alcohol Depend 2011; 114(2-3): 242-5.
74. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. Marijuana craving in the brain. Proc Natl Acad Sci USA 2009; 106(31): 13016-21.
75. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacology 2010; 35(4): 967-75.
76. Hermann D, Sartorius A, Welzel H, et al. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry 2007; 61(11): 1281-9.
77. Jacobsen LK, Mencl WE, Westerveld M, Pugh KR. Impact of cannabis use on brain function in adolescents. Ann N Y Acad Sci 2004; 1021: 384-90.
78. Leroy C, Karila L, Martinot JL, et al. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a highresolution PET study. Addict Biol 2012; 17(6): 981-90.
79. Mata I, Perez-Iglesias R, Roiz-Santianez R, et al. Gyrification brain abnormalities associated with adolescence and early-adulthood cannabis use. Brain Res 2010; 1317: 297-304.
80. Medina KL, Nagel BJ, Park A, McQueeny T, Tapert SF. Depressive symptoms in adolescents: associations with white matter volume and marijuana use. J Child Psychol Psychiatry 2007; 48(6): 592-600.
81. Murphy K, Dixon V, LaGrave K, et al. A validation of eventrelated FMRI comparisons between users of cocaine, nicotine, or cannabis and control subjects. Am J Psychiatry 2006; 163(7): 1245-51.
82. Nestor L, Roberts G, Garavan H, Hester R. Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users. Neuroimage 2008; 40(3): 1328-39.
83. Parkar SR, Ramanathan S, Nair N, et al. Cannabis dependence: Effects of cannabis consumption on inter-regional cerebral metabolic relationships in an Indian population. Indian J Psychiatry 2010; 52(3): 236-42.
84. Prescot AP, Locatelli AE, Renshaw PF, Yurgelun-Todd DA. Neurochemical alterations in adolescent chronic marijuana smokers: a proton MRS study. Neuroimage 2011; 57(1): 69-75.
85. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 2008; 13(2): 253-63.
86. Smith AM, Longo CA, Fried PA, Hogan MJ, Cameron I. Effects of marijuana on visuospatial working memory: an fMRI study in young adults. Psychopharmacology (Berl) 2010; 210(3): 429-38.
87. Wiesbeck GA, Taeschner KL. A cerebral computed tomography study of patients with drug-induced psychoses. Eur Arch Psychiatry Clin Neurosci 1991; 241(2): 88-90.
88. Wilson W, Mathew R, Turkington T, et al. Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis 2000; 19(1): 1-22.
89. Cohen M, Rasser PE, Peck G, et al. Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. Int J Neuropsychopharmacol 2011; 1-11.
90. Cornelius JR, Aizenstein HJ, Hariri AR. Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression. Addict Behav 2010; 35(6): 644-6.
91. Cowan RL, Joers JM, Dietrich MS. N-acetylaspartate (NAA) correlates inversely with cannabis use in a frontal language processing region of neocortex in MDMA (Ecstasy) polydrug users: a 3 T magnetic resonance spectroscopy study. Pharmacol Biochem Behav 2009; 92(1): 105-10.
92. Dekker N, Schmitz N, Peters BD, et al. Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res 2010; 181(1): 51-6.
93. Habets P, Marcelis M, Gronenschild E, Drukker M, van OJ. Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol Psychiatry 2011; 69(5): 487-94.
94. Ho BC, Wassink TH, Ziebell S, Andreasen NC. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res 2011; 128(1-3): 66-75.
95. Jacobus J, McQueeny T, Bava S, et al. White matter integrity in adolescents with histories of marijuana use and binge drinking. Neurotoxicol Teratol 2009; 31(6): 349-55.
96. James A, Hough M, James S, et al. Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). Schizophr Res 2011; 128(1-3): 91-7.
97. Kumra S, Robinson P, Tambyraja R, et al. Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders. J Am Acad Child Adolesc Psychiatry 2012; 51(2): 171-80.
98. Li CS, Milivojevic V, Constable RT, Sinha R. Recent cannabis abuse decreased stress-induced BOLD signals in the frontal and cingulate cortices of cocaine dependent individuals. Psychiatry Res 2005; 140(3): 271-80.
99. Parkar SR, Ramanathan S, Nair N, et al. Are the effects of cannabis dependence on glucose metabolism similar to schizophrenia? An FDG PET understanding. Indian J Psychiatry 2011; 53(1): 13-20.
100. Peters BD, de HL, Vlieger EJ, et al. Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity? Psychopharmacol Bull 2009; 42(2): 75-88.
101. Rais M, van Haren NE, Cahn W, et al. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur Neuropsychopharmacol 2010; 20(12): 855-65.
102. Roberts GM, Garavan H. Evidence of increased activation underlying cognitive control in ecstasy and cannabis users. Neuroimage 2010; 52(2): 429-35.
103. Safont G, Corripio I, Escarti MJ, et al. Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: an in vivo SPECT study. Schizophr Res 2011; 129(2-3): 169-71.
104. Schweinsburg AD, Schweinsburg BC, Cheung EH, et al. fMRI response to spatial working memory in adolescents with comorbid marijuana and alcohol use disorders. Drug Alcohol Depend 2005; 79(2): 201-10.
105. Solowij N, Yucel M, Respondek C, et al. Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychol Med 2011; 41(11): 2349-59.
106. Sundram S. Cannabis and neurodevelopment: implications for psychiatric disorders. Hum Psychopharmacol 2006; 21(4): 245-54.
107. Takagi M, Lubman DI, Walterfang M, et al. Corpus callosum size and shape alterations in adolescent inhalant users. Addict Biol 2011; Sep 29. [Epub ahead of print].
108. Tanabe J, Thompson L, Claus E, et al. Prefrontal cortex activity is reduced in gambling and nongambling substance users during decision-making. Hum Brain Mapp 2007; 28(12): 1276-86.
109. Voytek B, Berman SM, Hassid BD, et al. Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers. Synapse 2005; 57(2): 113-5.
110. Welch KA, McIntosh AM, Job DE, et al. The impact of substance use on brain structure in people at high risk of developing schizophrenia. Schizophr Bull 2011; 37(5): 1066-76.
111. Welch KA, Stanfield AC, McIntosh AM, et al. Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia. Br J Psychiatry 2011; 199: 386-90.
112. Wobrock T, Sittinger H, Behrendt B, D'Amelio R, Falkai P. Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur Arch Psychiatry Clin Neurosci 2009; 259(1): 28-36.
113. Yucel M, Zalesky A, Takagi MJ, et al. White-matter abnormalities in adolescents with long-term inhalant and cannabis use: a diffusion magnetic resonance imaging study. J Psychiatry Neurosci 2010; 35(6): 409-12.
114. O'Leary DS, Block RI, Flaum M, et al. Acute marijuana effects on rCBF and cognition: a PET study. Neuroreport 2000; 11(17): 3835-41.
115. Cadogan AK, Alexander SP, Boyd EA, Kendall DA. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem 1997; 69(3): 1131-7.
116. Chan PK, Chan SC, Yung WH. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist. Neuroreport 1998; 9(4): 671-5.
117. Cheer JF, Marsden CA, Kendall DA, Mason R. Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study. Neuroscience 2000; 99(4): 661-7.
118. Foy MR, Teyler TJ, Vardaris RM. delta 9-THC and 17-betaestradiol in hippocampus. Brain Res Bull 1982; 8(4): 341-5.
119. Jentsch JD, Andrusiak E, Tran A, Bowers MB, Jr., Roth RH. Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 1997; 16(6): 426-32.
120. Jentsch JD, Wise A, Katz Z, Roth RH. Alpha-noradrenergic receptor modulation of the phencyclidine-and delta9-tetrahydrocannabinol-induced increases in dopamine utilization in rat prefrontal cortex. Synapse 1998; 28(1): 21-6.
121. Ma YL, Weston SE, Whalley BJ, Stephens GJ. The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. Br J Pharmacol 2008; 154(1): 204-15.
122. Melis M, Pistis M, Perra S, et al. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 2004; 24(1): 53-62.
123. Miller AS, Walker JM. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur J Pharmacol 1996; 304(1-3): 29-35.
124. O'Neill C, Evers-Donnelly A, Nicholson D, O'Boyle KM, O'Connor JJ. D2 receptor-mediated inhibition of dopamine release in the rat striatum in vitro is modulated by CB1 receptors: studies using fast cyclic voltammetry. J Neurochem 2009; 108(3): 545-51.
125. Pandolfo P, Silveirinha V, dos Santos-Rodrigues A, et al. Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. Eur J Pharmacol 2011; 655(1-3): 38-45.
126. Poddar MK, Dewey WL. Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther 1980; 214(1): 63-7.
127. Rodriguez de FF, Fernandez-Ruiz JJ, Murphy LL, et al. Acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas. Pharmacol Biochem Behav 1992; 42(2): 269-75.
128. Sakurai-Yamashita Y, Kataoka Y, Fujiwara M, Mine K, Ueki S. Delta 9-tetrahydrocannabinol facilitates striatal dopaminergic transmission. Pharmacol Biochem Behav 1989; 33(2): 397-400.
129. Sperlagh B, Windisch K, Ando RD, Sylvester VE. Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens. Neurochem Int 2009; 54(7): 452-7.
130. Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 1998; 85(2): 395-403.
131. Szabo B, Muller T, Koch H. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 1999; 73(3): 1084-9.
132. Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 2000; 97(1): 89-97.
133. Szabo B, Siemes S, Wallmichrath I. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci 2002; 15(12): 2057-61.
134. Bambico FR, Nguyen NT, Katz N, Gobbi G. Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission. Neurobiol Dis 2010; 37(3): 641-55.
135. Cadoni C, Valentini V, Di CG. Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission. J Neurochem 2008; 106(4): 1586-93.
136. Higuera-Matas A, Miguens M, Coria SM, et al. Sex-specific disturbances of the glutamate/GABA balance in the hippocampus of adult rats subjected to adolescent cannabinoid exposure. Neuropharmacology 2012; 62(5-6): 1975-84.
137. Hill MN, Froc DJ, Fox CJ, Gorzalka BB, Christie BR. Prolonged cannabinoid treatment results in spatial working memory deficits and impaired long-term potentiation in the CA1 region of the hippocampus in vivo. Eur J Neurosci 2004; 20(3): 859-63.
138. Hoffman AF, Oz M, Caulder T, Lupica CR. Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci 2003; 23(12): 4815-20.
139. Hoffman AF, Oz M, Yang R, Lichtman AH, Lupica CR. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learn Mem 2007; 14(1-2): 63-74.
140. Lecca D, Cacciapaglia F, Valentini V, Di CG. Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration. Psychopharmacology (Berl) 2006; 188(1): 63-74.
141. Mato S, Robbe D, Puente N, Grandes P, Manzoni OJ. Presynaptic homeostatic plasticity rescues long-term depression after chronic Delta 9-tetrahydrocannabinol exposure. J Neurosci 2005; 25(50): 11619-27.
142. Nava F, Carta G, Colombo G, Gessa GL. Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze. Neuropharmacology 2001; 41(3): 392-9.
143. Robledo P, Trigo JM, Panayi F, de la Torre R, Maldonado R. Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Psychopharmacology (Berl) 2007; 195(2): 255-64.
144. Tanda G, Loddo P, Di CG. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 1999; 376(1-2): 23-6.
145. Whitlow CT, Freedland CS, Porrino LJ. Functional consequences of the repeated administration of Delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend 2003; 71(2): 169-77.
146. Wu X, French ED. Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology 2000; 39(3): 391-8.
147. Cheer JF, Kendall DA, Mason R, Marsden CA. Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum. Neuropharmacology 2003; 44(5): 633-41.
148. French ED. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 1997; 226(3): 159-62.
149. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997; 8(3): 649-52.
150. Gifford AN, Gardner EL, Ashby CR, Jr. The effect of intravenous administration of delta-9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats. Neuropsychobiology 1997; 36(2): 96-9.
151. Massi L, Elezgarai I, Puente N, et al. Cannabinoid receptors in the bed nucleus of the stria terminalis control cortical excitation of midbrain dopamine cells in vivo. J Neurosci 2008; 28(42): 10496-508.
152. Murillo-Rodriguez E, Palomero-Rivero M, Millan-Aldaco D, Mechoulam R, Drucker-Colin R. Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats. Life Sci 2011; 88(11-12): 504-11.
153. Ng Cheong Ton JM, Gerhardt GA, Friedemann M, et al. The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res 1988; 451(1-2): 59-68.
154. Pistis M, Porcu G, Melis M, Diana M, Gessa GL. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci 2001; 14(1): 96-102.
155. Pistis M, Muntoni AL, Pillolla G, Gessa GL. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. Eur J Neurosci 2002; 15(11): 1795-802.
156. Pistis M, Ferraro L, Pira L, et al. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 2002; 948(1-2): 155-8.
157. Wu WC, Wang Y, Chai CY. Acute effects of the cannabinoid receptor agonist WIN55212-2 on dopamine release in rat: an in vivo electrochemical study. Chin J Physiol 2008; 51(3): 152-9.
158. Arnone D, Barrick TR, Chengappa S, et al. Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage 2008; 41(3): 1067-74.
159. Ashtari M, Cervellione K, Cottone J, et al. Diffusion abnormalities in adolescents and young adults with a history of heavy cannabis use. J Psychiatr Res 2009; 43(3): 189-204.
160. Ashtari M, Avants B, Cyckowski L, et al. Medial temporal structures and memory functions in adolescents with heavy cannabis use. J Psychiatr Res 2011; 45(8): 1055-66.
161. Bava S, Frank LR, McQueeny T, et al. Altered white matter microstructure in adolescent substance users. Psychiatry Res 2009; 173(3): 228-37.
162. Bava S, Jacobus J, Mahmood O, Yang TT, Tapert SF. Neurocognitive correlates of white matter quality in adolescent substance users. Brain Cogn 2010; 72(3): 347-54.
163. Block RI, O'Leary DS, Ehrhardt JC, et al. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 2000; 11(3): 491-6.
164. Block RI, O'Leary DS, Hichwa RD, et al. Cerebellar hypoactivity in frequent marijuana users. Neuroreport 2000; 11(4): 749-53.
165. Block RI, O'Leary DS, Hichwa RD, et al. Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 2002; 72(1-2): 237-50.
166. Clark DB, Chung T, Thatcher DL, Pajtek S, Long EC. Psychological dysregulation, white matter disorganization and substance use disorders in adolescence. Addiction 2012; 107(1): 206-14.
167. Co BT, Goodwin DW, Gado M, Mikhael M, Hill SY. Absence of cerebral atrophy in chronic cannabis users. Evaluation by computerized transaxial tomography. JAMA 1977; 237(12): 1229-30.
168. Cousijn J, Wiers RW, Ridderinkhof KR, et al. Grey matter alterations associated with cannabis use: Results of a VBM study in heavy cannabis users and healthy controls. Neuroimage 2012; 59(4): 3845-51.
169. DeLisi LE, Bertisch HC, Szulc KU, et al. A preliminary DTI study showing no brain structural change associated with adolescent cannabis use. Harm Reduct J 2006; 3: 17.
170. Gruber SA, Yurgelun-Todd DA. Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Brain Res Cogn Brain Res 2005; 23(1): 107-18.
171. Gruber SA, Rogowska J, Yurgelun-Todd DA. Altered affective response in marijuana smokers: an FMRI study. Drug Alcohol Depend 2009; 105(1-2): 139-53.
172. Gruber SA, Silveri MM, Dahlgren MK, Yurgelun-Todd D. Why so impulsive? White matter alterations are associated with impulsivity in chronic marijuana smokers. Exp Clin Psychopharmacol 2011; 19(3): 231-42.
173. Hannerz J, Hindmarsh T. Neurological and neuroradiological examination of chronic cannabis smokers. Ann Neurol 1983; 13(2): 207-10.
174. Jager G, Kahn RS, van den Brink W, van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology (Berl) 2006; 185(3): 358-68.
175. Jager G, van Hell HH, De Win MM, et al. Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur Neuropsychopharmacol 2007; 17(4): 289-97.
176. Kim DJ, Skosnik PD, Cheng H, et al. Structural network topology revealed by white matter tractography in cannabis users: a graph theoretical analysis. Brain Connect 2011; 1(6): 473-83.
177. Kuehnle J, Mendelson JH, Davis KR, New PF. Computed tomographic examination of heavy marijuana smokers. JAMA 1977; 237(12): 1231-2.
178. Lopez-Larson MP, Bogorodzki P, Rogowska J, et al. Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav Brain Res 2011; 220(1): 164-72.
179. Mathew RJ, Wilson WH, Tant SR. Acute changes in cerebral blood flow associated with marijuana smoking. Acta Psychiatr Scand 1989; 79(2): 118-28.
180. Mathew RJ, Wilson WH, Turkington TG, et al. Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Res 2002; 116(3): 173-85.
181. Matochik JA, Eldreth DA, Cadet JL, Bolla KI. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 2005; 77(1): 23-30.
182. McQueeny T, Padula CB, Price J, et al. Gender effects on amygdala morphometry in adolescent marijuana users. Behav Brain Res 2011; 224(1): 128-34.
183. Medina KL, McQueeny T, Nagel BJ, et al. Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects. Addict Biol 2009; 14(4): 457-68.
184. Medina KL, Nagel BJ, Tapert SF. Abnormal cerebellar morphometry in abstinent adolescent marijuana users. Psychiatry Res 2010; 182(2): 152-9.
185. Tzilos GK, Cintron CB, Wood JB, et al. Lack of hippocampal volume change in long-term heavy cannabis users. Am J Addict 2005; 14(1): 64-72.
186. Ward PB, Solowij N, Peters R, et al. An fMRI study of regional brain volumes in long-term cannabis users. Journal of Psychopharmacology 2002; 16 (Suppl. 3)(A56).
187. Yucel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008; 65(6): 694-701.
188. Abdullaev Y, Posner MI, Nunnally R, Dishion TJ. Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. Behav Brain Res 2010; 215(1): 45-57.
189. Bolla KI, Eldreth DA, Matochik JA, Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 2005; 26(2): 480-92.
190. Chang L, Yakupov R, Cloak C, Ernst T. Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain 2006; 129(Pt 5): 1096-112.
191. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage 2004; 23(3): 914-20.
192. Harding IH, Solowij N, Harrison BJ, et al. Functional connectivity in brain networks underlying cognitive control in chronic cannabis users. Neuropsychopharmacology 2012; 37(8): 1923-33.
193. Hester R, Nestor L, Garavan H. Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users. Neuropsychopharmacology 2009; 34(11): 2450-8.
194. Hirvonen J, Goodwin RS, Li CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers. Mol Psychiatry 2012; 17(6): 642-9.
195. Jager G, Block RI, Luijten M, Ramsey NF. Cannabis use and memory brain function in adolescent boys: a cross-sectional multicenter functional magnetic resonance imaging study. J Am Acad Child Adolesc Psychiatry 2010; 49(6): 561-72, 572.
196. Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology (Berl) 2004; 176(3-4): 239-47.
197. King GR, Ernst T, Deng W, et al. Altered brain activation during visuomotor integration in chronic active cannabis users: relationship to cortisol levels. J Neurosci 2011; 31(49): 17923-31.
198. Lundqvist T, Jonsson S, Warkentin S. Frontal lobe dysfunction in long-term cannabis users. Neurotoxicol Teratol 2001; 23(5): 437-43.
199. Nestor L, Hester R, Garavan H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. Neuroimage 2010; 49(1): 1133-43.
200. Padula CB, Schweinsburg AD, Tapert SF. Spatial working memory performance and fMRI activation interaction in abstinent adolescent marijuana users. Psychol Addict Behav 2007; 21(4): 478-87.
201. Pillay SS, Rogowska J, Kanayama G, et al. Neurophysiology of motor function following cannabis discontinuation in chronic cannabis smokers: an fMRI study. Drug Alcohol Depend 2004; 76(3): 261-71.
202. Schweinsburg AD, Nagel BJ, Schweinsburg BC, et al. Abstinent adolescent marijuana users show altered fMRI response during spatial working memory. Psychiatry Res 2008; 163(1): 40-51.
203. Schweinsburg AD, Schweinsburg BC, Medina KL, et al. The influence of recency of use on fMRI response during spatial working memory in adolescent marijuana users. J Psychoactive Drugs 2010; 42(3): 401-12.
204. Schweinsburg AD, Schweinsburg BC, Nagel BJ, Eyler LT, Tapert SF. Neural correlates of verbal learning in adolescent alcohol and marijuana users. Addiction 2011; 106(3): 564-73.
205. Sevy S, Smith GS, Ma Y, et al. Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology (Berl) 2008; 197(4): 549-56.
206. Silveri MM, Jensen JE, Rosso IM, Sneider JT, Yurgelun-Todd DA. Preliminary evidence for white matter metabolite differences in marijuana-dependent young men using 2D J-resolved magnetic resonance spectroscopic imaging at 4 Tesla. Psychiatry Res 2011; 191(3): 201-11.
207. Sneider JT, Pope HG, Jr., Silveri MM, et al. Altered regional blood volume in chronic cannabis smokers. Exp Clin Psychopharmacol 2006; 14(4): 422-8.
208. Stokes PR, Egerton A, Watson B, et al. History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol 2012; 26(1): 144-9.
209. Tapert SF, Schweinsburg AD, Drummond SP, et al. Functional MRI of inhibitory processing in abstinent adolescent marijuana users. Psychopharmacology (Berl) 2007; 194(2): 173-83.
210. Vaidya JG, Block RI, O'Leary DS, et al. Effects of chronic marijuana use on brain activity during monetary decision-making. Neuropsychopharmacology 2012; 37(3): 618-29.
211. van Hell HH, Vink M, Ossewaarde L, et al. Chronic effects of cannabis use on the human reward system: an fMRI study. Eur Neuropsychopharmacol 2010; 20(3): 153-63.
212. Volkow ND, Gillespie H, Mullani N, et al. Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res 1996; 67(1): 29-38.
213. Weinstein A, Brickner O, Lerman H, et al. Brain imaging study of the acute effects of Delta9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology (Berl) 2008; 196(1): 119-31.
214. Wesley MJ, Hanlon CA, Porrino LJ. Poor decision-making by chronic marijuana users is associated with decreased functional responsiveness to negative consequences. Psychiatry Res 2011; 191(1): 51-9.
215. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 2001; 107(3): 173-7.
216. Wolff V, Lauer V, Rouyer O, et al. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke 2011; 42(6): 1778-80.
217. Volkow ND, Gillespie H, Mullani N, et al. Cerebellar metabolic activation by delta-9-tetrahydro-cannabinol in human brain: a study with positron emission tomography and 18F-2-fluoro-2-deoxyglucose. Psychiatry Res 1991; 40(1): 69-78.
218. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE. Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 1992; 12(5): 750-8.
219. Mathew RJ, Wilson WH. Acute changes in cerebral blood flow after smoking marijuana. Life Sci 1993; 52(8): 757-67.
220. Mathew RJ, Wilson WH, Coleman RE, Turkington TG, Degrado TR. Marijuana intoxication and brain activation in marijuana smokers. Life Sci 1997; 60(23): 2075-89.
221. Mathew RJ, Wilson WH, Turkington TG, Coleman RE. Cerebellar activity and disturbed time sense after THC. Brain Res 1998; 797(2): 183-9.
222. Mathew RJ, Wilson WH, Chiu NY, et al. Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 1999; 100(1): 67-75.
223. van Hell HH, Bossong MG, Jager G, et al. Evidence for involvement of the insula in the psychotropic effects of THC in humans: a double-blind, randomized pharmacological MRI study. Int J Neuropsychopharmacol 2011; 14(10): 1377-88.
224. Crippa JA, Zuardi AW, Garrido GE, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004; 29(2): 417-26.
225. O'Leary DS, Block RI, Koeppel JA, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 2002; 26(6): 802-16.
226. O'Leary DS, Block RI, Turner BM, et al. Marijuana alters the human cerebellar clock. Neuroreport 2003; 14(8): 1145-51.
227. O'Leary DS, Block RI, Koeppel JA, et al. Effects of smoking marijuana on focal attention and brain blood flow. Hum Psychopharmacol 2007; 22(3): 135-48.
228. Bossong MG, Jager G, van Hell HH, et al. Effects of Delta9-Tetrahydrocannabinol Administration on Human Encoding and Recall Memory Function: A Pharmacological fMRI Study. J Cogn Neurosci 2012; 24(3): 588-99.
229. Bossong MG, Jansma JM, van Hell HH, et al. Effects of delta9-tetrahydrocannabinol on human working memory function. Biol Psychiatry 2012; 71(8): 693-9.
230. Phan KL, Angstadt M, Golden J, et al. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 2008; 28(10): 2313-9.
231. Rabinak CA, Sripada CS, Angstadt M, de WH, Phan KL. Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect. J Neural Transm 2012; 119(6): 701-7.
232. van Hell HH, Jager G, Bossong MG, et al. Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology (Berl) 2012; 219(4): 981-90.
233. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009; 66(4): 442-51.
234. Bhattacharyya S, Crippa JA, Allen P, et al. Induction of psychosis by {delta}9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 2012; 69(1): 27-36.
235. Borgwardt SJ, Allen P, Bhattacharyya S, et al. Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 2008; 64(11): 966-73.
236. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009; 66(1): 95-105.
237. Winton-Brown TT, Allen P, Bhattacharyya S, et al. Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology 2011; 36(7): 1340-8.
238. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010; 13(4): 421-32.
239. Bossong MG, van Berckel BN, Boellaard R, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34(3): 759-66.
240. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 2009; 48(1): 186-90.
241. Barkus E, Morrison PD, Vuletic D, et al. Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol 2011; 25(11): 1462-8.
242. Freedland CS, Whitlow CT, Miller MD, Porrino LJ. Dosedependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse 2002; 45(2): 134-42.
243. Margulies JE, Hammer RP, Jr. Delta 9-tetrahydrocannabinol alters cerebral metabolism in a biphasic, dose-dependent manner in rat brain. Eur J Pharmacol 1991; 202(3): 373-8.
244. Pontieri FE, Conti G, Zocchi A, Fieschi C, Orzi F. Metabolic mapping of the effects of WIN 55212-2 intravenous administration in the rat. Neuropsychopharmacology 1999; 21(6): 773-6.
245. Whitlow CT, Freedland CS, Porrino LJ. Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat. Psychopharmacology (Berl) 2002; 161(2): 129-36.
246. Bloom AS, Tershner S, Fuller SA, Stein EA. Cannabinoid-induced alterations in regional cerebral blood flow in the rat. Pharmacol Biochem Behav 1997; 57(4): 625-31.
247. Goldman H, Dagirmanjian R, Drew WG, Murphy S. delta9-tetrahydrocannabinol alters flow of blood to subcortical areas of the conscious rat brain. Life Sci 1975; 17(3): 477-82.
248. Stein EA, Fuller SA, Edgemond WS, Campbell WB. Selective effects of the endogenous cannabinoid arachidonylethanolamide (anandamide) on regional cerebral blood flow in the rat. Neuropsychopharmacology 1998; 19(6): 481-91.
249. Nguyen VH, Verdurand M, Dedeurwaerdere S, et al. Increased brain metabolism after acute administration of the synthetic cannabinoid HU210: A small animal PET imaging study with (18)F-FDG. Brain Res Bull 2012; 87(2-3): 172-9.
250. Castañeda E, Moss DE, Oddie SD, Whishaw IQ. THC does not affect striatal dopamine release: microdialysis in freely moving rats. Pharmacol Biochem Behav 1991; 40(3): 587-91.
251. Chen J, Paredes W, Lowinson JH, Gardner EL. Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol 1990; 190(1-2): 259-62.
252. Chen J, Marmur R, Pulles A, Paredes W, Gardner EL. Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana'S psychoactive ingredient. Brain Res 1993; 621(1): 65-70.
253. Chen JP, Paredes W, Lowinson JH, Gardner EL. Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci Lett 1991; 129(1): 136-80.
254. Malone DT, Taylor DA. Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br J Pharmacol 1999; 128(1): 21-6.
255. Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colin R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 2006; 580(18): 4337-45.
256. Solinas M, Justinova Z, Goldberg SR, Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 2006; 98(2): 408-19.
257. Solinas M, Tanda G, Justinova Z, et al. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinollike discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 2007; 321(1): 370-80.
258. Tanda G, Pontieri FE, Di CG. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997; 276(5321): 2048-50.
259. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 2004; 24(18): 4393-400.
260. Diana M, Melis M, Gessa GL. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 1998; 10(9): 2825-30.
261. Gessa GL, Melis M, Muntoni AL, Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998; 341(1): 39-44.
262. Melis M, Gessa GL, Diana M. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24(6): 993-1006.
263. Corchero J, Manzanares J, Fuentes JA. Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 2004; 16(1-2): 159-72.
264. Fattore L, Cossu G, Spano MS, et al. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol 2004; 16(1-2): 147-58.
265. Fattore L, Deiana S, Spano SM, et al. Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol Biochem Behav 2005; 81(2): 343-59.
266. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35(1): 217-38.
267. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005; 79(1): 59-68.
268. D'Souza DC, Braley G, Blaise R, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 2008; 198(4): 587-603.